BR9914491A - Process for producing a functional immunoglobulin superfamily protein - Google Patents
Process for producing a functional immunoglobulin superfamily proteinInfo
- Publication number
- BR9914491A BR9914491A BR9914491-3A BR9914491A BR9914491A BR 9914491 A BR9914491 A BR 9914491A BR 9914491 A BR9914491 A BR 9914491A BR 9914491 A BR9914491 A BR 9914491A
- Authority
- BR
- Brazil
- Prior art keywords
- protein
- immunoglobulin
- cell
- functional
- mhc class
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Patente de Invenção: "MéTODO DE PRODUçãO DE UMA PROTEìNA DE SUPERFAMìLIA DE IMUNOGLOBULINA FUNCIONAL". A presente invenção refere-se a um processo para produção de uma proteína de superfamília de imunoglobulina funcional, a qual apresenta pelo menos uma ligação de dissulfeto quando funcional, o processo compreendendo as etapas de prover um célula bacteriana compreendendo um gene codificado para a proteína, o gene sendo expressável na dita célula, cultivar a célula sob condições onde o gene seja expressado, isolar a proteína da célula sem reduzi-Ia e submeter a proteína isolada a um tratamento de dobra. De preferêncía, a proteína de superfamília de imunoglobulina é selecionada do grupo consistindo em anticorpos, regiões variáveis (V) de imunoglubulina, regíões constantes (C) de imunoglobulina, cadeia leves de imunoglobulina, cadeias pesadas de imunoglobulina, CD1, CD2, CD3, moléculas histocompatíveis de Classe I e Classe II, <225>~ 2~microglobulina(<225>~ 2~m), antígeno-3 (LFA-3) com função associada de linfócito e FcyRIII, CD7, CD8, Thy-1 e Tp44 (CD28), receptor de célula T, CD4, receptor de poli-imunoglobulina, molécula de adesão de célula neuronal (NCAM), glicoproteína associada com mielina (MAG), proteína de mielina P, antígeno carcino-embriónico (CEA), receptor de fator de crescimento derivado de plaqueta (PDGFR), receptor de fator-1 de simulção de colónia, <244><225>-glicoproteína, ICAM (molécula de adesão intercelular), interleucinas e plaquetas. Concretizações importantes da invenção são uma proteína de MHC livre de peptídio estável obtenível por um processo da invenção e um kit compreendendo uma cadeia pesada de classe I de MHC e uma <225>~ 2~m permitindo que o recipiente produza e meça ou detecte uma proteína de classe I de MHC ao qual um peptídio, que é capaz de se ligar à dita proteína de classe I de MHC, pode ser adicionado levando à geração de uma proteína de classe I de MHC funcional.Invention Patent: "METHOD OF PRODUCTION OF A FUNCTIONAL IMMUNOGLOBULIN SUPERFAMILY PROTEIN". The present invention relates to a process for producing a functional immunoglobulin superfamily protein, which has at least one disulfide bond when functional, the process comprising the steps of providing a bacterial cell comprising a gene encoded for the protein, the gene being expressable in said cell, cultivating the cell under conditions where the gene is expressed, isolating the protein from the cell without reducing it and subjecting the isolated protein to a fold treatment. Preferably, the immunoglobulin superfamily protein is selected from the group consisting of antibodies, immunoglobulin variable (V) regions, immunoglobulin constant (C) regions, immunoglobulin light chains, immunoglobulin heavy chains, CD1, CD2, CD3, molecules histocompatible Class I and Class II, <225> ~ 2 ~ microglobulin (<225> ~ 2 ~ m), antigen-3 (LFA-3) with associated lymphocyte and FcyRIII, CD7, CD8, Thy-1 and Tp44 function (CD28), T-cell receptor, CD4, poly-immunoglobulin receptor, neuronal cell adhesion molecule (NCAM), myelin-associated glycoprotein (MAG), myelin P protein, carcino-embryonic antigen (CEA), platelet-derived growth factor (PDGFR), colony simulation factor-1 receptor, <244> <225> -glycoprotein, ICAM (intercellular adhesion molecule), interleukins and platelets. Important embodiments of the invention are a stable peptide-free MHC protein obtainable by a process of the invention and a kit comprising an MHC class I heavy chain and a <225> ~ 2 ~ m allowing the container to produce and measure or detect a MHC class I protein to which a peptide, which is able to bind to said MHC class I protein, can be added leading to the generation of a functional MHC class I protein.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA199801155 | 1998-09-14 | ||
| PCT/DK1999/000484 WO2000015665A2 (en) | 1998-09-14 | 1999-09-14 | A method of producing a functional immunoglobulin superfamily protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9914491A true BR9914491A (en) | 2002-01-15 |
Family
ID=8101632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9914491-3A BR9914491A (en) | 1998-09-14 | 1999-09-14 | Process for producing a functional immunoglobulin superfamily protein |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1114063A2 (en) |
| JP (1) | JP2002524104A (en) |
| KR (1) | KR20010075108A (en) |
| CN (1) | CN1326466A (en) |
| AU (1) | AU771239C (en) |
| BR (1) | BR9914491A (en) |
| CA (1) | CA2343313A1 (en) |
| MX (1) | MXPA01002674A (en) |
| NZ (1) | NZ511031A (en) |
| WO (1) | WO2000015665A2 (en) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2336167T3 (en) | 2001-03-14 | 2019-09-02 | Dako Denmark As | MHC molecular constructs and their use in diagnosis and therapy |
| AU2003223936A1 (en) * | 2002-05-17 | 2003-12-02 | Kobenhavns Universitet | Method for purifying denatured proteins having a desired disulfide bond configuration |
| US20040072262A1 (en) * | 2002-10-11 | 2004-04-15 | Montero-Julian Felix A. | Methods and systems for detecting MHC class I binding peptides |
| WO2004072112A2 (en) * | 2003-02-11 | 2004-08-26 | Københavns Universitet | A method for formulating mhc-like molecules for long time storage |
| WO2005043121A2 (en) * | 2003-10-31 | 2005-05-12 | Vitatex, Inc. | Blood test prototypes and methods for the detection of circulating tumor and endothelial cells |
| WO2006009838A2 (en) | 2004-06-17 | 2006-01-26 | Beckman Coulter, Inc. | Mycobacterium tuberculosis epitopes and methods of use thereof |
| JP4959566B2 (en) | 2004-08-19 | 2012-06-27 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Folding of transforming growth factor β family proteins |
| TWI501774B (en) | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | Treatments for neurological disorders |
| CL2007002225A1 (en) * | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A |
| EP2361930A3 (en) | 2007-03-26 | 2011-10-26 | Dako Denmark A/S | Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases |
| US8329655B2 (en) | 2007-05-01 | 2012-12-11 | Biogen Idec Ma Inc. | Methods for increasing vascularization |
| EP3023436A1 (en) | 2007-07-03 | 2016-05-25 | Dako Denmark A/S | Improved methods for generation, labeling and use of mhc multimers |
| SI3597659T1 (en) | 2007-07-09 | 2023-04-28 | Genentech, Inc. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
| WO2009039854A2 (en) | 2007-09-27 | 2009-04-02 | Dako Denmark A/S | Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics |
| GB2453589A (en) | 2007-10-12 | 2009-04-15 | King S College London | Protease inhibition |
| US10968269B1 (en) | 2008-02-28 | 2021-04-06 | Agilent Technologies, Inc. | MHC multimers in borrelia diagnostics and disease |
| US10722562B2 (en) | 2008-07-23 | 2020-07-28 | Immudex Aps | Combinatorial analysis and repair |
| GB0817244D0 (en) | 2008-09-20 | 2008-10-29 | Univ Cardiff | Use of a protein kinase inhibitor to detect immune cells, such as T cells |
| US10369204B2 (en) | 2008-10-02 | 2019-08-06 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| CN103364558A (en) * | 2013-07-17 | 2013-10-23 | 江阴泽成生物技术有限公司 | Human tumor marker carcinoembryonic antigen (CEA) magnetic particle chemiluminiscence immunoassay kit and detection method |
| CN109402036A (en) * | 2018-11-07 | 2019-03-01 | 河北科技师范学院 | The application of ox source Salmonella enteritidis trxB gene delection |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5314813A (en) * | 1992-02-19 | 1994-05-24 | Scripps Research Institute | Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines |
| WO1993022332A2 (en) * | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| AU4923593A (en) * | 1992-09-15 | 1994-04-12 | Rockefeller University, The | Major histocompatibility complex molecules and modifications thereof |
| CA2175089A1 (en) * | 1993-10-25 | 1995-05-04 | Eric T. Rhodes | Prokaryotic expression of mhc proteins |
| AU3036597A (en) * | 1996-05-21 | 1997-12-09 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method for using peptide complexes/major histocompatibility complex to obtain or purify antigen-specific t cells and to stimulate t cells |
-
1999
- 1999-09-14 MX MXPA01002674A patent/MXPA01002674A/en unknown
- 1999-09-14 EP EP99941420A patent/EP1114063A2/en not_active Withdrawn
- 1999-09-14 CN CN99813211A patent/CN1326466A/en active Pending
- 1999-09-14 AU AU55047/99A patent/AU771239C/en not_active Ceased
- 1999-09-14 KR KR1020017003306A patent/KR20010075108A/en not_active Application Discontinuation
- 1999-09-14 JP JP2000570203A patent/JP2002524104A/en active Pending
- 1999-09-14 BR BR9914491-3A patent/BR9914491A/en not_active IP Right Cessation
- 1999-09-14 WO PCT/DK1999/000484 patent/WO2000015665A2/en not_active Application Discontinuation
- 1999-09-14 CA CA002343313A patent/CA2343313A1/en not_active Abandoned
- 1999-09-14 NZ NZ511031A patent/NZ511031A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20010075108A (en) | 2001-08-09 |
| CN1326466A (en) | 2001-12-12 |
| CA2343313A1 (en) | 2000-03-23 |
| MXPA01002674A (en) | 2002-06-04 |
| WO2000015665A2 (en) | 2000-03-23 |
| JP2002524104A (en) | 2002-08-06 |
| WO2000015665A3 (en) | 2000-08-17 |
| EP1114063A2 (en) | 2001-07-11 |
| AU5504799A (en) | 2000-04-03 |
| AU771239C (en) | 2004-10-14 |
| NZ511031A (en) | 2003-11-28 |
| AU771239B2 (en) | 2004-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9914491A (en) | Process for producing a functional immunoglobulin superfamily protein | |
| Morita et al. | Functionally distinct subsets of human γ/δ T cells | |
| Cooper et al. | A novel cell surface molecule on early B-lineage cells | |
| Mannu et al. | Role of hemichrome binding to erythrocyte membrane in the generation of band-3 alterations in beta-thalassemia intermedia erythrocytes | |
| Davis | Intercellular transfer of cell-surface proteins is common and can affect many stages of an immune response | |
| Parham | Monoclonal antibodies against two separate alloantigenic sites of HLA-1340 | |
| Mäkelä et al. | Lack of heterogeneity in anti-hapten antibodies of a phylogenetically primitive shark | |
| BRPI0511782B8 (en) | anti-cd3 antibodies, use and method of production thereof, pharmaceutical composition, isolated nucleic acid molecule and vector | |
| Goding | Allotypes of IgM and IgD receptors in the mouse: a probe for lymphocyte differentiation | |
| US20220042008A1 (en) | COMPOSITIONS OF STREPTAVIDIN-OLIGO CONJUGATES OF pMHC OCCUPANCY | |
| Cook et al. | Structural Studies on the Murine Ia Alloantigens: II. Molecular Qeight Characterization of the Products of the IA and IE/C Subregions | |
| AU595159B2 (en) | Bispecific antibody determinants | |
| Andrew et al. | Engineered cupredoxins and bacterial cytochrome c oxidases have similar CuA sites: Evidence from resonance Raman spectroscopy | |
| Gazit et al. | Alloantigens of the human T (HT) genetic region of the HLA linkage group | |
| Wilson et al. | Unraveling the mysteries of γδ T cell recognition | |
| Zola | Monoclonal antibodies against human cell membrane antigens: A review | |
| Paletta et al. | The hypervariable region 4 (HV4) and position 93 of the α chain modulate CD1d‐glycolipid binding of iNKT TCRs | |
| Navarrete | Human leucocyte antigens | |
| Halloran et al. | The specificity and significance of the inhibition of Fc receptor binding by anti H-2 sera | |
| Dickler et al. | B-lymphocyte Fc receptor-associated non-H-2 antigens are determined by a single polymorphic locus which is linked of the Mls locus | |
| Lafarge | What compatibility in 2017 for the haematopoietic stem cell transplantation? | |
| Huang et al. | Glycophorin He (Sta) of the human red blood cell membrane is encoded by a complex hybrid gene resulting from two recombinational events | |
| Schendel et al. | T cells specific for different antigens express different HLA‐D region products | |
| Nesse et al. | A comparison of lymphocyte antigen specificities in Norwegian and Swiss goats | |
| Parham | Functional sites of human class I MHC molecules: paradigms a dozen? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A, 8A E 9A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008. |